首页> 外文会议>Scale-up and manufacturing of cell-based therapies V >A SYSTEMS APPROACH FOR CAR T CELL THERAPY PRODUCT CHARACTERIZATION
【24h】

A SYSTEMS APPROACH FOR CAR T CELL THERAPY PRODUCT CHARACTERIZATION

机译:汽车细胞治疗产品表征的系统方法

获取原文
获取原文并翻译 | 示例

摘要

In general, there are three principle parameters by which investigators assess CAR-Ts in the clinical setting: clinical outcome, CAR-T cell persistence, and patient safety. CAR-Ts are "living drugs"; short of clinical trials, it is currently not possible to assess CAR-T safety and efficacy based on in vitro taxonomies of cell phenotype and function. This talk will discuss systems wide analytical strategies that may enable for the more comprehensive and precise characterization of CAR-T products with an overall objective of developing safer and more effective therapies for patients.
机译:通常,研究人员可通过三个主要参数在临床环境中评估CAR-T:临床结果,CAR-T细胞持久性和患者安全性。 CAR-T是“活体药物”;由于缺乏临床试验,目前尚无法根据细胞表型和功能的体外分类法评估CAR-T的安全性和有效性。本讲座将讨论系统范围的分析策略,这些策略可能使CAR-T产品更全面,更准确地表征,其总体目标是为患者开发更安全,更有效的疗法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号